Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is on a positive trajectory with a strong management team, best-in-class products, and structural tailwinds. While the recent updates from the management team have led to a lowered top-line guidance, the company's up-sized debt capacity and equity raise demonstrate a commitment to long-term growth. However, execution and stability within the sales force will be crucial for TELA to continue to take market share and achieve operational leverage.

Bears say

TELA Bio is facing challenges in its sales team reorganization and go-to-market strategy, leading to lowered revenue guidance for FY26 by nearly half of previous expectations. While the company has solid unit volume growth and a renewed territory strategy, their reliance on reimbursement and potential for future losses and dilution remains a concern. Additionally, there is still much to prove in terms of execution and accelerating business momentum, despite the company's strong product portfolio. These factors contribute to the negative outlook for TELA Bio's stock.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Jun 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.